149 related articles for article (PubMed ID: 38643301)
1. Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.
Martin T; Rioufol C; Favier B; Martelli N; Madelaine I; Chouaid C; Borget I
BioDrugs; 2024 May; 38(3):465-475. PubMed ID: 38643301
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
[TBL] [Abstract][Full Text] [Related]
3. Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.
Tuppin P; Rudant J; Constantinou P; Gastaldi-Ménager C; Rachas A; de Roquefeuil L; Maura G; Caillol H; Tajahmady A; Coste J; Gissot C; Weill A; Fagot-Campagna A
Rev Epidemiol Sante Publique; 2017 Oct; 65 Suppl 4():S149-S167. PubMed ID: 28756037
[TBL] [Abstract][Full Text] [Related]
4. [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].
Baudouin A; Fargier E; Cerruti A; Dubromel A; Vantard N; Ranchon F; Schwiertz V; Salles G; Souquet PJ; Thomas L; Bérard F; Nancey S; Freyer G; Trillet-Lenoir V; Rioufol C
Bull Cancer; 2017 Jun; 104(6):538-551. PubMed ID: 28237353
[TBL] [Abstract][Full Text] [Related]
5. Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).
Albin N; Chassagnol F; Bergmann JF; ;
Therapie; 2019 Feb; 74(1):103-117. PubMed ID: 30745156
[TBL] [Abstract][Full Text] [Related]
6. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
8. Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Bessou A; Colin X; De Nascimento J; Sopwith W; Ferrante S; Gorsh B; Gutierrez B; Sansbury L; Willson J; Sapra S; Paka P; Wang F
Eur J Health Econ; 2023 Apr; 24(3):321-333. PubMed ID: 35610398
[TBL] [Abstract][Full Text] [Related]
9. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
10. [Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma].
Auger C; Guillot B; Monard A; Albin N
Bull Cancer; 2022 Jan; 109(1):28-37. PubMed ID: 34972538
[TBL] [Abstract][Full Text] [Related]
11. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
Pham FY; Jacquet E; Taleb A; Monard A; Kerouani-Lafaye G; Turcry F; Brunel L; Grudé F; Yoldjian I; Sainte-Marie I; Boudali L; Blay JY; Albin N
Int J Cancer; 2022 Oct; 151(8):1345-1354. PubMed ID: 35603979
[TBL] [Abstract][Full Text] [Related]
12. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
13. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
[TBL] [Abstract][Full Text] [Related]
14. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
15. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
DeMartino PC; Miljkovic MD; Prasad V
JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
[TBL] [Abstract][Full Text] [Related]
16. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.
Polak TB; van Rosmalen J; Uyl-de Groot CA
Br J Clin Pharmacol; 2020 Sep; 86(9):1819-1826. PubMed ID: 32200551
[TBL] [Abstract][Full Text] [Related]
17. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
18. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
[TBL] [Abstract][Full Text] [Related]
19. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
[No Abstract] [Full Text] [Related]
20. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
